IN2014CN02805A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02805A IN2014CN02805A IN2805CHN2014A IN2014CN02805A IN 2014CN02805 A IN2014CN02805 A IN 2014CN02805A IN 2805CHN2014 A IN2805CHN2014 A IN 2805CHN2014A IN 2014CN02805 A IN2014CN02805 A IN 2014CN02805A
- Authority
- IN
- India
- Prior art keywords
- compounds
- medicaments
- variables
- inhibitors
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161547301P | 2011-10-14 | 2011-10-14 | |
PCT/US2012/059932 WO2013056034A1 (en) | 2011-10-14 | 2012-10-12 | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN02805A true IN2014CN02805A (de) | 2015-07-03 |
Family
ID=47116434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2805CHN2014 IN2014CN02805A (de) | 2011-10-14 | 2012-10-12 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9079929B2 (de) |
EP (1) | EP2766347B1 (de) |
JP (1) | JP6033318B2 (de) |
CN (1) | CN103987696B (de) |
ES (1) | ES2579832T3 (de) |
IN (1) | IN2014CN02805A (de) |
WO (1) | WO2013056034A1 (de) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011215898B2 (en) | 2010-02-11 | 2016-08-11 | Bristol-Myers Squibb Company | Macrocycles as Factor XIa inhibitors |
TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子xia抑制劑之新穎巨環化合物 |
TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為xia因子抑制劑之環狀p1接合劑 |
ES2579832T3 (es) | 2011-10-14 | 2016-08-17 | Bristol-Myers Squibb Company | Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa |
SG11201401384UA (en) | 2011-10-14 | 2014-09-26 | Bristol Myers Squibb Co | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
CN103987697B (zh) | 2011-10-14 | 2017-04-26 | 百时美施贵宝公司 | 作为因子xia抑制剂的取代的四氢异喹啉化合物 |
EP2876105A4 (de) | 2012-07-19 | 2016-01-13 | Sumitomo Dainippon Pharma Co Ltd | 1- (cycloalkyl-carbonyl)prolinderivat |
BR112015002293A2 (pt) | 2012-08-03 | 2017-07-04 | Bristol Myers Squibb Co | di-hidropiridona pi como inibidores do fator xia |
US9409908B2 (en) | 2012-08-03 | 2016-08-09 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor XIa inhibitors |
EP2906552B1 (de) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidinsubstituierte tetrahydroisochinoline als factor xia inhibitoren |
WO2014059214A1 (en) * | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
CN104837833B (zh) | 2012-10-12 | 2017-07-14 | 百时美施贵宝公司 | Xia因子抑制剂的晶型 |
JP6367245B2 (ja) * | 2013-03-05 | 2018-08-01 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 植物の収量を向上させるためのアシルスルホンアミド類の使用 |
ES2712699T3 (es) * | 2013-03-25 | 2019-05-14 | Bristol Myers Squibb Co | Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa |
WO2015054087A1 (en) | 2013-10-07 | 2015-04-16 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
CN116987080A (zh) | 2014-01-31 | 2023-11-03 | 百时美施贵宝公司 | 作为因子xia抑制剂的具有杂环p2′基团的大环化合物 |
NO2760821T3 (de) | 2014-01-31 | 2018-03-10 | ||
EP3104702B1 (de) | 2014-02-11 | 2022-08-10 | Merck Sharp & Dohme LLC | Faktor-xia-hemmer |
EP3104703B1 (de) | 2014-02-11 | 2020-11-18 | Merck Sharp & Dohme Corp. | Faktor-xia-hemmer |
WO2015164308A1 (en) | 2014-04-22 | 2015-10-29 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
US9365520B2 (en) | 2014-07-01 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
EP3180317B1 (de) | 2014-07-28 | 2021-04-14 | Merck Sharp & Dohme Corp. | Faktor-xia-inhibitoren |
JP6526796B2 (ja) | 2014-09-04 | 2019-06-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Fxia阻害剤であるジアミドマクロ環 |
EP3197880B1 (de) | 2014-09-24 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung |
US10167280B2 (en) | 2014-09-24 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
JP6742348B2 (ja) | 2015-06-19 | 2020-08-19 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 第xia因子阻害剤としてのジアミド大員環 |
JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
EP3328851B1 (de) | 2015-07-29 | 2020-04-22 | Bristol-Myers Squibb Company | Makrocyclische inhibitoren von xia-faktor mit alkyl- oder cycloalkyl-p2'-gruppen |
CN114874222A (zh) | 2015-07-29 | 2022-08-09 | 百时美施贵宝公司 | 携带非芳族p2,基团的因子xia新大环 |
US10336730B2 (en) | 2015-08-05 | 2019-07-02 | Bristol-Myers Squibb Company | Substituted glycine derived FXIA inhibitors |
EP3371162B1 (de) | 2015-10-29 | 2022-01-26 | Merck Sharp & Dohme Corp. | Makrocyclische spirocarbamat-derivate als faktor-xia-inhibitoren, pharmazeutisch verträgliche zusammensetzungen und deren verwendung |
BR112018008506B8 (pt) | 2015-10-29 | 2023-12-05 | Merck Sharp & Dohme | Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos |
WO2017123518A1 (en) * | 2016-01-11 | 2017-07-20 | The Rockefeller University | Aminotriazole immunomodulators for treating autoimmune diseases |
KR102382188B1 (ko) * | 2016-03-17 | 2022-04-05 | 주식회사 체크메이트테라퓨틱스 | NamPT 억제용 신규 화합물 및 이를 포함하는 조성물 |
TW201808908A (zh) | 2016-08-22 | 2018-03-16 | 美商默沙東藥廠 | 因子XIa抑制劑 |
CN113912586B (zh) | 2016-08-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
CN109721539B (zh) * | 2017-10-27 | 2021-07-09 | 天津药物研究院有限公司 | 吡唑酰胺类衍生物及其制备方法和用途 |
CN109867660A (zh) * | 2017-12-01 | 2019-06-11 | 四川科伦博泰生物医药股份有限公司 | 含季铵离子的四氢异喹啉酰胺化合物及其药物用途 |
JP7458984B2 (ja) * | 2018-03-28 | 2024-04-01 | 四川科倫博泰生物医薬股▲フン▼有限公司 | テトラヒドロイソキノリン系誘導体、その製造方法及び用途 |
US20220235033A1 (en) * | 2019-05-30 | 2022-07-28 | Merck Sharp & Dohme Corp. | Factor xi activation inhibitors |
US20230147170A1 (en) * | 2020-04-01 | 2023-05-11 | Merck Sharp & Dohme Llc | Factor xi activation inhibitors |
EP3978487A1 (de) | 2020-09-30 | 2022-04-06 | Origo Biopharma, S.L. | 2-(3-pyridin-2-yl-4-chinolin-4-yl-pyrazol-1-yl)-acetamid-derivate als inhibitoren des transformierenden wachstumsfaktor-beta-rezeptors i/alk5 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1525186A (fr) | 1967-03-29 | 1968-05-17 | Roussel Uclaf | Nouvelles pénicillines et procédé de préparation |
DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
DE4034829A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | Cyclopeptide |
JP3190431B2 (ja) | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | ケトン誘導体 |
GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
WO1996034010A2 (en) | 1995-03-29 | 1996-10-31 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5624936A (en) | 1995-03-29 | 1997-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5869682A (en) | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU717298B2 (en) | 1996-04-03 | 2000-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
WO2000077027A2 (en) | 1999-06-14 | 2000-12-21 | Tularik Limited | Serine protease inhibitors |
PT1064298E (pt) | 1998-03-19 | 2009-01-02 | Vertex Pharma | Inibidores de caspasas |
YU73300A (sh) | 1998-05-26 | 2003-08-29 | Warner-Lambert Company | Biciklični pirimidini i biciklični 3,4-dihidropirimidini kao inhibitori ćelijske proliferacije |
US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
EP1016663A1 (de) | 1999-01-02 | 2000-07-05 | Aventis Pharma Deutschland GmbH | Neue Malonsäure Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung und pharmazeutische Zusammensetzungen sie enthaltend (Inhibierung der Faktor Xa Aktivität) |
JP2002534420A (ja) | 1999-01-02 | 2002-10-15 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 新規なマロン酸誘導体、その調製方法、その使用およびそれを含有する医薬組成物(Xa因子活性阻害) |
DE50008510D1 (de) | 1999-04-09 | 2004-12-09 | Abbott Gmbh & Co Kg | Niedermolekulare inhibitoren von komplementproteasen |
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
EP1125925A1 (de) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amin-Derivate zur Behandlung von Apoptosis |
ES2252230T3 (es) | 2000-05-11 | 2006-05-16 | Bristol-Myers Squibb Company | Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento. |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
PL204653B1 (pl) | 2001-09-21 | 2010-01-29 | Bristol Myers Squibb Co | Pochodna pirazolo [3, 4-c] pirydyny, jej zastosowanie i kompozycja farmaceutyczna |
AU2002357692A1 (en) * | 2001-11-09 | 2003-05-26 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
EP1660439A2 (de) | 2003-08-08 | 2006-05-31 | Transtech Pharma, Inc. | Aryl- und heteroarylverbindungen, zusammensetzungen und anwendungsverfahren |
US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
AU2005271831A1 (en) | 2004-07-12 | 2006-02-16 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
JP5236293B2 (ja) | 2005-01-13 | 2013-07-17 | ブリストル−マイヤーズ スクイブ カンパニー | Xia因子阻害剤としての置換ビアリール化合物 |
US20060183771A1 (en) | 2005-02-17 | 2006-08-17 | Seiffert Dietmar A | Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors |
AU2006259075B2 (en) | 2005-06-17 | 2012-02-09 | Basf Se | Process of producing bleach boosters |
US8163749B2 (en) | 2005-12-14 | 2012-04-24 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
US7626039B2 (en) | 2005-12-14 | 2009-12-01 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors |
US8466295B2 (en) | 2005-12-14 | 2013-06-18 | Bristol-Myers Squibb Company | Thiophene derivatives as factor XIa inhibitors |
CA2661462C (en) | 2006-08-23 | 2015-09-29 | Valeant Pharmaceuticals International | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
CN101605779B (zh) | 2006-12-15 | 2013-11-20 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物 |
TW200848024A (en) | 2007-06-13 | 2008-12-16 | Bristol Myers Squibb Co | Dipeptide analogs as coagulation factor inhibitors |
EP2265601B1 (de) | 2008-03-13 | 2012-02-01 | Bristol-Myers Squibb Company | Pyridazinderivate als faktor-xia-inhibitoren |
WO2010151317A1 (en) | 2009-06-22 | 2010-12-29 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
WO2011002520A2 (en) | 2009-07-02 | 2011-01-06 | Angion Biomedica Corp. | Small molecule inhibitors of parp activity |
WO2011017296A1 (en) | 2009-08-04 | 2011-02-10 | Schering Corporation | 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
AU2011215898B2 (en) | 2010-02-11 | 2016-08-11 | Bristol-Myers Squibb Company | Macrocycles as Factor XIa inhibitors |
EP2729150B1 (de) | 2011-07-08 | 2016-09-14 | Merck Sharp & Dohme Corp. | Faktor-ixa-hemmer |
TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子xia抑制劑之新穎巨環化合物 |
TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為xia因子抑制劑之環狀p1接合劑 |
CN103987697B (zh) | 2011-10-14 | 2017-04-26 | 百时美施贵宝公司 | 作为因子xia抑制剂的取代的四氢异喹啉化合物 |
ES2579832T3 (es) | 2011-10-14 | 2016-08-17 | Bristol-Myers Squibb Company | Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa |
SG11201401384UA (en) | 2011-10-14 | 2014-09-26 | Bristol Myers Squibb Co | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
KR102011534B1 (ko) | 2011-12-21 | 2019-08-16 | 오노 야꾸힝 고교 가부시키가이샤 | 인자 XIa 억제제로서 피리디논 및 피리미디논 유도체 |
WO2013111107A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | Aminopyridine derivatives as plasma kallikrein inhibitors |
WO2013111108A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | 3位置換プロリン誘導体 |
LT2847228T (lt) | 2012-05-10 | 2018-11-12 | Bayer Pharma Aktiengesellschaft | Antikūnai, galintys jungtis prie koaguliacijos faktoriaus xi ir (arba) jo aktyvuotos formos faktoriaus xia, ir jų panaudojimas |
EP2876105A4 (de) | 2012-07-19 | 2016-01-13 | Sumitomo Dainippon Pharma Co Ltd | 1- (cycloalkyl-carbonyl)prolinderivat |
US9409908B2 (en) | 2012-08-03 | 2016-08-09 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor XIa inhibitors |
BR112015002293A2 (pt) | 2012-08-03 | 2017-07-04 | Bristol Myers Squibb Co | di-hidropiridona pi como inibidores do fator xia |
-
2012
- 2012-10-12 ES ES12780357.5T patent/ES2579832T3/es active Active
- 2012-10-12 US US14/350,411 patent/US9079929B2/en active Active
- 2012-10-12 EP EP12780357.5A patent/EP2766347B1/de active Active
- 2012-10-12 IN IN2805CHN2014 patent/IN2014CN02805A/en unknown
- 2012-10-12 CN CN201280061628.1A patent/CN103987696B/zh active Active
- 2012-10-12 WO PCT/US2012/059932 patent/WO2013056034A1/en active Application Filing
- 2012-10-12 JP JP2014535916A patent/JP6033318B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP6033318B2 (ja) | 2016-11-30 |
US9079929B2 (en) | 2015-07-14 |
US20140274960A1 (en) | 2014-09-18 |
JP2014530240A (ja) | 2014-11-17 |
WO2013056034A1 (en) | 2013-04-18 |
CN103987696B (zh) | 2016-12-21 |
EP2766347B1 (de) | 2016-05-04 |
ES2579832T3 (es) | 2016-08-17 |
CN103987696A (zh) | 2014-08-13 |
EP2766347A1 (de) | 2014-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN02805A (de) | ||
IN2014CN02806A (de) | ||
TN2014000155A1 (en) | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors | |
MX2015000892A (es) | Dihidropiridona p1 como inhibidores del factor xia. | |
MX361370B (es) | Dihidropiridona p1 como inhibidores del factor xia. | |
PH12016500072B1 (en) | Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof | |
EP4219465A3 (de) | Prmt5-inhibitoren und verwendungen davon | |
UA108442C2 (ru) | Индазолы | |
PH12015500064B1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
IN2015DN01156A (de) | ||
IN2014MN02658A (de) | ||
NZ708382A (en) | Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents | |
IN2014MN02657A (de) | ||
MY162936A (en) | Macrocycles as factor xia inhibitors | |
AU2012214029A8 (en) | Rorgammat inhibitors | |
MX2014014229A (es) | Pirrolidina-2-carboxamidas sustituidas. | |
UA111382C2 (uk) | Інгібітори протеїнкінази | |
IN2015DN00598A (de) | ||
MX2016000675A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos. | |
IN2015DN00185A (de) | ||
IN2014CN03803A (de) | ||
JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
IN2014DN06869A (de) | ||
GB201209587D0 (en) | Therapeutic compounds | |
MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. |